Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

ILiAD Biotechnologies

ILiAD Biotechnologies?uq=w9if130k
2012 FOUNDED
PRIVATE STATUS
Angel LATEST DEAL TYPE
$8M LATEST DEAL AMOUNT
1 INVESTORS
Description

Provider of a technology to prevent bordetella pertussis. The company is focused on the eradication of whooping cough by developing an improved pertussis vaccine.

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Biotechnology
Primary Office
  • 230 East 15th Street
  • Suite 1-A
  • New York, NY 10003
  • United States

+1 (954) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore ILiAD Biotechnologies’s full profile, request a free trial.

ILiAD Biotechnologies Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Angel (individual) 13-Apr-2017 $8M 000.00 Completed Clinical Trials - Phase 1
3. Angel (individual) 13-Nov-2015 00000 00.000 Completed Clinical Trials - Phase 1
2. Grant $10M $3.81M Completed Clinical Trials - Phase 1
1. Angel (individual) $3.81M $3.81M Completed Clinical Trials - Phase 1
To view this company’s complete deal history including valuation and funding, request access »

ILiAD Biotechnologies Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
European Union Government 000 0000 000000 0

ILiAD Biotechnologies Executive Team (2)

Name Title Board
Seat
Contact
Info
Keith Rubin MD Founder & Chief Executive Officer
Walter Greenblatt Chief Financial Officer